Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The TREAT Asia HIV Observational Database: baseline and retrospective data.
Zhou J, Kumarasamy N, Ditangco R, Kamarulzaman A, Lee CK, Li PC, Paton NI, Phanuphak P, Pujari S, Vibhagool A, Wong WW, Zhang F, Chuah J, Frost KR, Cooper DA, Law MG; TREAT Asia HIV Observational Database. Zhou J, et al. Among authors: paton ni. J Acquir Immune Defic Syndr. 2005 Feb 1;38(2):174-9. doi: 10.1097/01.qai.0000145351.96815.d5. J Acquir Immune Defic Syndr. 2005. PMID: 15671802 Free PMC article.
Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis.
Kanters S, Socias ME, Paton NI, Vitoria M, Doherty M, Ayers D, Popoff E, Chan K, Cooper DA, Wiens MO, Calmy A, Ford N, Nsanzimana S, Mills EJ. Kanters S, et al. Among authors: paton ni. Lancet HIV. 2017 Oct;4(10):e433-e441. doi: 10.1016/S2352-3018(17)30109-1. Epub 2017 Aug 4. Lancet HIV. 2017. PMID: 28784426 Review.
HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.
Kityo C, Thompson J, Nankya I, Hoppe A, Ndashimye E, Warambwa C, Mambule I, van Oosterhout JJ, Wools-Kaloustian K, Bertagnolio S, Easterbrook PJ, Mugyenyi P, Walker AS, Paton NI; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. Kityo C, et al. Among authors: paton ni. J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):e45-e54. doi: 10.1097/QAI.0000000000001285. J Acquir Immune Defic Syndr. 2017. PMID: 28129253 Free PMC article.
Neurocognitive Function at the First-Line Failure and on the Second-Line Antiretroviral Therapy in Africa: Analyses From the EARNEST Trial.
Kambugu A, Thompson J, Hakim J, Tumukunde D, van Oosterhout JJ, Mwebaze R, Hoppe A, Abach J, Kwobah C, Arenas-Pinto A, Walker SA, Paton NI; EARNEST Trial Team. Kambugu A, et al. Among authors: paton ni. J Acquir Immune Defic Syndr. 2016 Apr 15;71(5):506-13. doi: 10.1097/QAI.0000000000000898. J Acquir Immune Defic Syndr. 2016. PMID: 26579985 Clinical Trial.
Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis.
Stockdale AJ, Saunders MJ, Boyd MA, Bonnett LJ, Johnston V, Wandeler G, Schoffelen AF, Ciaffi L, Stafford K, Collier AC, Paton NI, Geretti AM. Stockdale AJ, et al. Among authors: paton ni. Clin Infect Dis. 2018 Jun 1;66(12):1846-1857. doi: 10.1093/cid/cix1108. Clin Infect Dis. 2018. PMID: 29272346 Free PMC article.
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
Paton NI, Kityo C, Thompson J, Nankya I, Bagenda L, Hoppe A, Hakim J, Kambugu A, van Oosterhout JJ, Kiconco M, Bertagnolio S, Easterbrook PJ, Mugyenyi P, Walker AS; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. Paton NI, et al. Lancet HIV. 2017 Aug;4(8):e341-e348. doi: 10.1016/S2352-3018(17)30065-6. Epub 2017 May 8. Lancet HIV. 2017. PMID: 28495562 Free PMC article. Clinical Trial.
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.
Hakim JG, Thompson J, Kityo C, Hoppe A, Kambugu A, van Oosterhout JJ, Lugemwa A, Siika A, Mwebaze R, Mweemba A, Abongomera G, Thomason MJ, Easterbrook P, Mugyenyi P, Walker AS, Paton NI; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. Hakim JG, et al. Among authors: paton ni. Lancet Infect Dis. 2018 Jan;18(1):47-57. doi: 10.1016/S1473-3099(17)30630-8. Epub 2017 Nov 3. Lancet Infect Dis. 2018. PMID: 29108797 Free PMC article. Clinical Trial.
Impact of tuberculosis on the body composition of HIV-infected men in Brazil.
Paton NI, Castello-Branco LR, Jennings G, Ortigao-de-Sampaio MB, Elia M, Costa S, Griffin GE. Paton NI, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Mar 1;20(3):265-71. doi: 10.1097/00042560-199903010-00008. J Acquir Immune Defic Syndr Hum Retrovirol. 1999. PMID: 10077175
Evaluation of cerebrospinal fluid virological escape in patients on long-term protease inhibitor monotherapy.
Arenas-Pinto A, Stöhr W, Clarke A, Williams I, Beeching NJ, Minton J, Lee V, Paton NI; Protease Inhibitor monotherapy Versus Ongoing Triple therapy (PIVOT) CNS sub-study Team. Arenas-Pinto A, et al. Among authors: paton ni. Antivir Ther. 2017;22(6):535-538. doi: 10.3851/IMP3146. Epub 2017 Feb 24. Antivir Ther. 2017. PMID: 28234235 Free PMC article.
143 results